11,448 Results

Phase III FeDeriCa study of Perjeta + Herceptin meets secondary endpoint in breast cancer.- Genentech/Roche + Halozyme Therapeutics

 Added 10 hours ago

Halozyme Therapeutics announced that new data from the global phase III FeDeriCa study conducted by Genentech/Roche will be presented at...

Kite/Gilead submits BLA to FDA for KTE X19 to treat relapsed or refractory mantle cell lymphoma.

 Added 10 hours ago

Kite, a Gilead Company announced that it has submitted a Biologics License Application (BLA) to the FDA for the investigational...

Positive tucatinib HER2CLIMB trial results in locally advanced or metastatic HER2-positive breast cancer published in the NEJM Seattle Genetics

 Added 10 hours ago

Seattle Genetics, Inc. announced positive pivotal data from the HER2CLIMB trial evaluating tucatinib in patients with HER2-positive metastatic breast cancer...

European Commission approves Evenity for severe osteoporosis.- Amgen + UCB

 Added 10 hours ago

Amgen and UCB announced that the European Commission has granted marketing authorization for Evenity (romosozumab) for the treatment of severe...

Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal phase II HER2-positive metastatic breast cancer trial (DESTINY-Breast01).- Daiichi Sankyo + AstraZeneca

 Added 10 hours ago

Daiichi Sankyo presented positive detailed data from the global pivotal phase II single-arm DESTINY-Breast01 trial of DS-8201 ([fam-] trastuzumab deruxtecan),...

FDA accepts supplemental biologics license application for Xolair for the treatment of nasal polyps.- Genentech/Roche

 Added 1 day ago

Genentech, a member of the Roche Group announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA)...

Merck Inc., to acquire ArQule Inc.,and with it ARQ 531 , oral Bruton's tyrosine kinase inhibitor to treat B-cell malignancies

 Added 1 day ago

Merck and ArQule, Inc.announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will...

Primary results from phase II ZUMA-2 trial of KTE X19 to treat relapsed or refractory mantle cell lymphoma. Kite/Gilead

 Added 1 day ago

Kite, a Gilead Company announced primary results from ZUMA-2 , a global, multicenter, single-arm, open-label Phase II study of KTE...

Phase III studies (ECZTRA 1-3) of CAT 354 meet primary endpoint in atopic dermatitis.- LEO Pharma

 Added 1 day ago

LEO Pharma announced that CAT 354 (tralokinumab) met all primary and secondary endpoints in its three pivotal Phase III studies...

Load more